All posts by medical

Cell Biology

Hamilton Thorne Reports Record Revenue for the Quarter and Year-Ended December 31, 2019 – GlobeNewswire

BEVERLY, Mass. and TORONTO, April 22, 2020 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the fourth quarter and year-ended December 31, 2019.

Financial Highlights

David Wolf, President and Chief Executive Officer of Hamilton Thorne Ltd., commented, 2019 was another significant year for Hamilton Thorne with record sales of $35.4 million and adjusted EBITDA of $7.1 million. We continued to invest in sales and support resources in the US and Germany and continued to enhance our operations in order to take better advantage of the cross-selling and marketing synergies between the North American and European-based businesses. We also completed a significant expansion of our product line, geographic coverage and scale when we acquired UK-based Planer Limited in August. As we move past the COVID-19 pandemic, we see a significant opportunity to grow revenues from the Planer product line by leveraging our established direct sales channels and expanding the business of other Hamilton Thorne brands through additional direct sales capabilities in the UK.

Commenting on the quarter, Mr. Wolf added, With sales of $10.8 million and adjusted EBITDA of approximately $2.2 million, this was a record quarter for Hamilton Thorne. We increased our EBITDA margin versus the rest of the year, while continuing to invest in R&D and sales and marketing resources. Sales were positively impacted by the addition of approximately $1.6 million of revenues from the newly acquired Planer business, significant growth in the Companys laser and image analysis systems business, increased consumables sales, and continued growth of the sale of third-party equipment in the US. Gross profit for the quarter was up versus the balance of the year at approximately 56.5% due to product mix, and relatively flat compared to the prior years fourth quarter.

All amounts are in US dollars, unless specified otherwise, and results, with the exception of Adjusted EBITDA, are expressed in accordance with the International Financial Reporting Standards ("IFRS").

Results of Operations for the year-ended December 31, 2019

Hamilton Thorne sales increased 21% to $35,358,409 for the year-ended December 31, 2019, an increase of $6,144,595 from $29,213,814 during the previous year. Sales were up due to organic growth in operations owned by the Company for more than one year augmented by the added revenues from the Planer acquisition. Sales into the human clinical market grew substantially, primarily driven by strong increases in the sales of third-party equipment, our own clinical instruments, particularly in the second half of the year, our newly introduced LYKOS DTSTM laser system, and Gynemed-branded consumables, augmented by the contribution from the Planer acquisition. Sales into the animal breeding markets were up slightly for the year while sales into the research and cell biology markets were up substantially, largely driven by the contribution from the Planer acquisition as well as strong toxicology systems sales in the fourth quarter.

Gross profit for the year increased 15% or $2,526,302 to $19,030,022 in the year-ended December 31, 2019, compared to $16,503,720 in the previous year, primarily as a function of sales growth. Gross profit as a percentage of sales was down at 53.8% for the year-ended December 31, 2019 versus 56.5% for 2018 primarily due to product mix, particularly the impact of additional direct sales of third-party products in the US, and the addition of somewhat lower margin sales of Planer products, partially offset by increases in direct sales of higher margin proprietary equipment, branded consumables, and quality control testing services sales.

Operating expenses increased 22% or $2,897,173 to $15,805,307 for the year-ended December 31, 2019, up from $12,908,134 for the previous year, primarily due to the addition of Planer expenses post-closing, increased acquisition expenses, and increased depreciation and amortization. Excluding acquisition-related expenses for both periods, operating expenses would have been up $2,272,174, or 18%. Operating expenses were also affected by continued strategic investments in research and development and sales and marketing resources.

Net interest expense decreased $47,233 from $1,151,455 to $ 1,104,222 for the year-ended December 31, 2019 versus the prior year primarily due to reductions in the Companys revolving line of credit, convertible debentures due to conversion, and other term loan borrowings, plus interest earned on the Companys cash balances, partially offset by increased term debt in August to partially finance the Planer acquisition.

The change in fair value of derivative decreased $846,199 for the year-ended December 31, 2019, from a gain of $572,621 in 2018 to a non-cash loss of $273,578, primarily due to the weakening of the euro, partially offset by the increase of the Companys share price between the measurement dates.

Net income decreased to $793,275 for the year-ended December 31, 2019, versus $2,960,355 for the prior year, primarily attributable to increased revenues and profitability for the relevant periods offset by increased operating expenses, the $846,199 change in fair value of derivative, increased income taxes, increased acquisition expense, and continued strategic investments in research and development and sales and marketing resources.

Adjusted EBITDA for the year-ended December 31, 2019 increased 15% to $7,096,012 versus $6,187,254 in the prior year, due to revenue and gross profit growth, partially offset by increased operating expenses in the periods.

Results of Operations for the Fourth Quarter ended December 31, 2019

For the three months ended December 31, 2019, sales were up 34% from $8,072,739 to $10,841,097. Gross profit was up 34% to $6,121,965 versus $4,574,835 for the prior year. Sales and gross profit were up due to organic growth in operations owned by the Company for more than one year augmented by the added revenues and gross profit from the Planer acquisition. Gross profit percentage decreased from 56.7% to 56.5% for the quarter, primarily due to product mix. Operating expenses were up 34% to $5,160,706 versus $3,842,854 for the prior year, primarily due to the addition of Planer operating expenses for the quarter.

In the fourth quarter of 2019, the Companys net income decreased to $930,581 while Adjusted EBITDA increased 28% to $2,233,064 versus net income of $2,745,020 and Adjusted EBITDA of $1,750,245 for the prior year fourth quarter. These changes were due primarily, in the case of net income, to the $939,562 change in the fair value of derivative and increased income taxes, and in the case of Adjusted EBITDA to increased sales and gross profits partially offset by increased operating expenses.

See the Companys published Management Discussion and Analysis for a reconciliation of Adjusted EBITDA to Net Income for the year and the quarter.

OUTLOOK

The recent outbreak of the coronavirus, or COVID-19, has added substantial uncertainty to the short- and mid-term outlook as the countries where the Company has significant operations have required entities to limit or suspend business operations and have implemented travel restrictions and quarantine measures.The Companys operations are deemed to be part of the essential medical infrastructure in most places where it has personnel and it has implemented business continuity plans, including work from home programs, to maintain operations.

While it is not possible at this time to estimate the impact that COVID-19 could have on the Company, the continued spread of COVID-19 and the measures taken by the governments of countries affected has and is expected to continue to affect the demand for certain of the Companys products and services and could disrupt the supply chain and the manufacture or shipment of product inventories and adversely impact the Companys business, financial condition or results of operations. The COVID-19 outbreak and mitigation measures may also have an adverse impact on global economic conditions which could have an adverse effect on the Companys business and financial condition. The extent to which the COVID-19 outbreak impacts the Companys results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.

Mr. Wolf commented, The first quarter of 2020 started off very strong. Our preliminary estimated results for Q1 are approximately $10.2 million in sales, which represents over 30% year over year growth and approximately 10% organic growth (approximately 12% constant currency). We did, however, see reduced demand for some of our products and services in certain territories as the quarter developed, as many IVF clinics reduced their activities. This reduction has continued in the second quarter, but we have also seen demand for our products return in some territories, notably China, which had been severely impacted in Q1. These fluctuations in demand for many of our products and services will last for a period of time that is difficult to determine, and will have an adverse effect on financial results in the second quarter, which could extend for one or more subsequent quarters. To improve our financial results, we have taken actions to reduce many non-essential expenses, reduce some personnel costs, and defer certain capital expenditures and new hiring.

Mr. Wolf continued, The Company has generated cash from operations since 2013 and, in normal circumstances, expected to generate cash from operations in 2020. Given the uncertainties surrounding the COVID-19 outbreak, it is impossible to predict whether the Company will generate cash from operations in 2020. Regardless, the Company currently maintains a strong balance sheet, with cash on hand of approximately $15.1 million, and net bank debt of approximately $10.1 million following the Companys Q1 drawdown under its line of credit, and believes that its current cash position should be sufficient to support operations for the next twelve months. We continue to work on our acquisition program with a goal of completing one or more meaningful acquisitions every twelve to eighteen months; however, the effects of the COVID-19 outbreak could affect this goal.

Mr. Wolf added, The COVID-19 virus will eventually run its course, and, we remain optimistic that once this happens, the strong macroeconomic and demographic tailwinds that have driven the growth of our business over the past few years will continue for the foreseeable future.

Conference Call

The Company will hold a conference call on Wednesday, April 22, 2020 at 11:00 a.m. EDT to review highlights of results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 7281879. The Companys updated investor presentation and a recording of the call will be available on Hamilton Thornes website shortly after the call.

Financial Statements and accompanying Management Discussion and Analysis for the periods are available on http://www.sedar.com and the Hamilton Thorne website.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thornes customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

The Company has included earnings before interest, income taxes, depreciation, amortization, share-based compensation expense, changes in fair value of derivatives and identified acquisition costs related to completed transactions (Adjusted EBITDA) as a non-IFRS measure, which is used by management as a measure of financial performance. See section entitled Use of Non-IFRS Measures and Results of Operations in the Companys Management Discussion and Analysis for the periods covered for further information and a reconciliation of Adjusted EBITDA to Net Income.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at http://www.sedar.com.

For more information, please contact:

David Wolf, President & CEO Hamilton Thorne Ltd. 978-921-2050 ir@hamiltonthorne.ltd

Glen AkselrodBristol Investor Relations905-326-1888glen@bristolir.com

Michael Bruns, CFOHamilton Thorne Ltd.978-921-2050ir@hamiltonthorne.ltd

Go here to see the original:
Hamilton Thorne Reports Record Revenue for the Quarter and Year-Ended December 31, 2019 - GlobeNewswire

Cell Biology

Male reproductive health problems could begin in womb – Mirage News

Disruptions to male babies development early during pregnancy could have a profound effect on a mans future reproductive health, according to new research.

A world-first finding into the gestation period when testes develop in the fetus has given researchers new insights into the potential causes of male infertility and testicular cancer later in life.

A Hudson Institute research team led by Professor Kate Loveland has discovered that a growth factor, activin A, is linked to steroid production in the testes in utero.

This research demonstrates for the first time that activin A is necessary for normal production of testosterone in the fetal testis, said Ms Whiley, a PhD student with the Testis Development and Male Germ Cell Biology group and the studys first author.

Published in the journal Endocrinology, the discovery shows that activin A promotes synthesis of two enzymes crucial for the final steps of testosterone synthesis, in a preclinical model. However, the absence of activin A resulted in an abnormal steroid environment.

Ms Whiley said the findings pinpoint an important growth period in utero when the testes are developing.

Events that alter activin A levels, which can occur due to different physiological conditions of pregnancy or the mothers exposure to certain medications, may explain why some boys and men have impaired reproductive health, Prof Loveland said.

Testicular cancer is the second most common cancer in young men aged 18-39. Reduced fertility affects one in 20 men. Both are increasingly common, but the causes of these disorders are not well understood. Disruptions occurring during fetal life may have a profound effect on a mans future reproductive health, she said.

The research provides a new understanding of how steroids are produced in the fetal testis. In addition, the key role of activin A highlights how formation of the earliest germline cells may be affected by factors in their environment.

This study is part of our ongoing research that aims to better understand the basis of male infertility and conditions such as hypospadias, cryptorchidism (see Key facts below) and testicular cancer, which are increasing worldwide, Prof Loveland said.

KEY FACTS

Funders | NHMRC

Collaborators | Professor David Handelsman (ANZAC Institute, Sydney, AUS), Professor Kristian Almstrup (Copenhagen University Hospital)

More here:
Male reproductive health problems could begin in womb - Mirage News

Cell Biology

Global Stem Cells Market with Focus on Clinical Therapies, 2020-2030 – Presents a Detailed Clinical Trial Analysis on More Than 540 Completed, Ongoing…

Dublin, April 22, 2020 (GLOBE NEWSWIRE) -- The "Global Stem Cells Market: Focus on Clinical Therapies, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.

Stem cell therapies are viable alternatives to conventional treatments with substantial therapeutic potential; market opportunities are huge, as multiple product candidates are expected to be approved over the coming decade

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for stem cell therapies over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved stem cell therapies.

The report also features the likely distribution of the current and forecasted opportunity within stem cell therapies market across:

According to the WHO, in 2020, nearly 75% of fatalities that are estimated to be reported across the globe, are likely to be caused due to diseases, such as chronic stroke disease, diabetes, cancer, heart disease, and certain mental health conditions. In addition, as per a report published by the Center for Managing Chronic Disease, University of Michigan, more than 50% of the global population was estimated to be living with some form of chronic illness.

The rising prevalence of these clinical conditions has resulted in dire need for the identification of effective therapeutic options. Despite advances in healthcare, there is an evident lack of permanent treatment solutions for many aforementioned diseases. Majority of the currently available treatment options focus on palliative care and are incapable of addressing the root cause of disease, therefore, are unable to improve quality of life of patients.

Since the first bone marrow transplant in 1950s, these regenerative cellular therapies have garnered significant attention within the biopharmaceutical industry. Over the years, advances in the field of cell biology and regenerative medicine have led to the development of a number of stem cell therapies, which are believed to possess the potential to address several unmet needs related to the treatment of a wide range of disease conditions. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, curing affiliated disease symptoms.

In fact, such interventions have also been shown to enable cell regeneration, restoring normal functioning capabilities in affected organs. Till date, nearly 25 stem cell-based therapies have been approved; popular examples include EYE-01M (2019), Alofisel (2018), MACI (2016), Stempeucel (2016) and Strimvelis (2016). Further, several such therapies are presently being evaluated across 540 active clinical trials worldwide. This emerging field of research has received significant capital investments from several big pharma companies and venture capital funds / investors.

Despite the associated optimism, the growth of this market is stunted by a number of development and manufacturing related challenges, primarily revolving around the limited availability of the required expertise and infrastructure to produce such products. However, the availability of innovative technology platforms, large target patient population, encouraging clinical trial results, and extensive government support, the stem cell therapies market is poised to grow in the long-term.

In addition to other elements, the study includes:

To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

Key Topics Covered

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION 3.1. Chapter Overview3.2. Overview of Stem Cell Therapies3.3. Regulatory Guidelines for Stem Cell Therapies3.4. Prevalent Trends Related to Stem Cell Therapies3.5. Growth Drivers and Roadblocks

4. MARKET LANDSCAPE4.1. Chapter Overview4.2. Stem Cell Therapies: Marketed and Development Pipeline4.3. Stem Cell Therapies: Additional Information4.4. Stem Cell Therapies: List of Technology Platforms4.5. Stem Cell Therapies: List of Therapy Developers4.6. Heptagon Representation: Analysis by Phase of Development and Key Therapeutic Area4.7. Grid Representation: Analysis by Phase of Development, Source of Stem Cell and Therapeutic Area4.8. Tree Map Representation: Analysis by Therapeutic Area and Size of the Company4.9. World Map Representation: Analysis of Regional Activity

5. COMPANY PROFILES5.1. Chapter Overview5.2. Anterogen5.2.1. Company Overview5.2.2. Product Portfolio: Clinical-Stage Stem Cell Therapies5.2.3. Recent Developments and Future Outlook5.3. Athersys5.4. CHA Biotech5.5. Cytopeutics5.6. Hope Biosciences5.7. Mesoblast5.8. Pluristem Therapeutics5.9. Takeda Pharmaceutical5.10. TICEBA

6. KEY THERAPEUTIC AREAS6.1. Chapter Overview6.2. Autoimmune / Inflammatory Disorders6.3. Cardiovascular Disorders6.4. Dermatological Disorders6.5. Metabolic Disorders6.6. Oncological Disorders6.7. Neurological Disorders

7. ANSOFF MATRIX EVALUATION7.1. Chapter Overview7.2. Established Therapeutic Areas in Established Regions7.2.1. Competition7.2.2. Growth Opportunities7.3. Established Therapeutic Areas in Emerging Regions7.4. Emerging Therapeutic Areas in Established Regions7.5. Emerging Therapeutic Areas in Emerging Regions

8. ACADEMIC GRANTS ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Stem Cell Therapies: Analysis of Grants Awarded by the National Institutes of Health (NIH)8.4. Grant Attractiveness Analysis

9. CLINICAL TRIAL ANALYSIS9.1. Chapter Overview9.2. Scope and Methodology9.3. Stem Cell Therapies: Clinical Trial Analysis

10. STEM CELL MANUFACTURING MARKET LANDSCAPE AND KPIs FOR EVALUATING CONTRACT SERVICES PARTNERS10.1. Chapter Overview10.2. Stem Cell Therapy Manufacturing10.3. Stem Cell Therapy Manufacturing: KPI Analysis10.4. Concluding Remarks

11. STEM CELL THERAPY DEVELOPERS AND CMOs: OPPORTUNITY ASSESSMENT11.1. Chapter Overview11.2. Therapy Developers and CMOs in North America11.3. Therapy Developers and CMOs in Europe11.4. Therapy Developers and CMOs in Asia-Pacific and Rest of the World11.5. Concluding Remarks

12. KEY COMMERCIALIZATION STRATEGIES12.1. Chapter Overview12.2. Successful Drug Launch Strategy: ROOTS Framework12.3. Successful Drug Launch Strategy: Product Differentiation12.4. Commonly Adopted Commercialization Strategies based on Stage of Product Development12.5. Key Approved Stem Cell Therapies: Profiles12.5.1. CARTISTEM12.5.2. HiQCell12.5.3. Prochymal12.5.4. Strimvelis12.6. Key Commercialization Strategies Adopted by Stem Cell Therapy Developers12.6.1. Strategies Adopted before Therapy Approval12.6.2. Strategies Adopted Post Therapy Approval12.7. Opportunities and Challenges with Unapproved Therapies12.8. Concluding Remarks

13. MARKET FORECAST13.1. Chapter Overview13.2. Scope and Limitations13.3. Forecast Methodology and Key Assumptions13.4. Overall Stem Cell Therapies Market, 2020-203013.5. Concluding Remarks

14. CONCLUSION

15. EXECUTIVE INSIGHTS15.1. Chapter Overview15.2. Seraxis15.3. Xcelthera15.4. Kadimastem15.5. Heartseed15.6. University of Rostock15.7. Bio Elpida15.8. Roslin Cell Therapies15.9. University of Minnesota15.10. Waisman Biomanufacturing15.11. YposKesi

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/aajvno

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Go here to read the rest:
Global Stem Cells Market with Focus on Clinical Therapies, 2020-2030 - Presents a Detailed Clinical Trial Analysis on More Than 540 Completed, Ongoing...

Cell Biology

Accelerating Antibody Discovery with Next-Generation Single-Cell Analysis – News-Medical.net

Why are therapeutic antibodies traditionally produced in vivo during early drug discovery?

Typically, in vivo models are used because they are cost-effective and relatively fast at generating candidate antibodies that can be tested. Introduced by Khler and Milstein in 1975, the traditional mouse hybridoma technique begins by injecting a validated or known antigen into the animal model, for example, mice, which causes an immune response that generates novel antibodies. These novel antibodies can then be harvested and fully characterized downstream to ensure that they have the desired molecular function and properties.

Image credit: extender_01 | Shutterstock

Scientific and technological advances have further improved in vivo studies. More recently, humanized mice have been immunized to express human immunoglobulins, rather than the mouse antibody genes, which enhances how translational these are downstream.

Animal models continue to be prevalent, primarily because they are tried and tested in the industry with good results. Despite the challenges, hybridoma technology is a well-established platform, and the humanization of animal models has further promoted this method. Most FDA approved therapeutics have been produced using humanized platforms.

However, fully rodent animal models can result in rodent specific immunogenicity and proteins from the animal model may remain at a later stage. In fact, not all antibodies produced in humanized animal models will be entirely human.

Other technologies, for instance, phage display provide a compelling alternative as they dont require animal models, have shorter timelines and researchers can use a fully human antibody library. These libraries can be quite diverse and can contain different constructs within them, for example, single-domain antibodies. Using next generation sequencing (NGS) with phage display helps characterize immunoglobulin genes from large populations, which better represents natural human antibodies.

Phage display isnt without downsides either; as it is a prokaryotic system rather than mammalian, there may be issues with affinity and other properties of this in vitro platform.

After successfully immunizing an animal, a lymphoid organ, for example, the spleen, is harvested. This is processed and B-cells are isolated. B-cells that produce antigen-specific antibodies that bind to the target antigen then need to be separated from those that bind to other antigens.

Next, the reactivity to the target antigen is tested to ensure that selected antibodies bind specifically to the antigen (rather than to a range of antigens) and that this affinity and sensitivity is above the required level. Once the unique B-cells have been isolated, scientists will screen for binding characteristics, cross-reactivity and more.

Research teams will typically use flow cytometry to screen the B-cells directly or more often produce hybridomas which are then screened.

Producing a hybridoma population requires a fusion reaction between the B-cell and a cancerous myeloma cell. This allows the B-cell to proliferate and survive indefinitely in culture, which is essential to safeguard potential cells of interest. Unfortunately, when creating hybridomas, the whole B-cell population is unable to be fused; therefore, only a fraction of the total population can be screened, thus leading to the loss of a large part of the B-cell repertoire.

Traditionally, flow cytometry is favored because of its high-throughput, and antibodies secreted from the B-cells can potentially be screened using cold capture, a technique used to manipulate the cell to prevent the full secretion of antibodies by trapping them at the cell surface. However, this is a representation rather than direct measurement of antibody secretion.

Alternative screening methods include ELISA and Elispot, which can measure B-cell secretion. Although these techniques often need to be completed manually, making them tedious and limited to low-scale screening.

A research team typically spends many months during this process cycle, from immunizing the animal model, collecting cells and creating hybridomas or directly screening B-cells. The population of target cells can be as low as 0.001% of the original ~40 million cells in the harvested organ. Further loss due to diminishing cell viability and cell death due to the harsh processing of these cells can severely impact productivity.

After completing this cycle, the target cells may not be found because they have either not been successfully fused during the hybridoma fusion process or died during culture due to the harsh processing. This is a big challenge in the industry.

The Cyto-Mine Single Cell Analysis System can overcome numerous challenges in the industry. First, the need for high-throughput yet gentle technology that enables the deep interrogation of whole B-cell repertoires and hybridoma populations while preserving cell viability. Second, the need for highly sensitive and specific assays to find rare antibody-secreting cells with the desired antibody characteristics.

Cyto-Mine can be used in screening entire cell populations to find that rare B-cell or hybridoma that secretes the antigen-specific antibody. In fact, researchers can input isolated B-cells directly into the Cyto-Mine, which drastically cuts down the process cycle timelines, and removes the possibility of losing cells in culture. Additionally, Cyto-Mine offers the flexibility in assay design, of which there is a great need due to the varying nature of the targets and the biologics.

Underpinned by Sphere Fluidics patented picodroplet technology, Cyto-Mine integrates the selective screening of tens of millions of single cells in miniaturized aqueous picoliter compartments called picodroplets.

Picodroplets provide individual micro-reaction chambers where secreted proteins accumulate and can be assayed to identify valuable proteins (e.g. antibodies with antigen-specificity), to find rare cells of interest or to find high-producing cells.

The picodroplets themselves provide a protective environment for the fragile B-cells, shielding them from shear stress as the picodroplets travel through the microfluidic channels. Cells can also be encapsulated in their preferred culture media, so there are no harmful culture transitions.

By combining B-cell isolation and identification of antigen-specific hits into a process that takes only 1-2 days in Cyto-Mine, you significantly reduce the stress on the fragile cells and accelerate the steps to downstream analysis such as functional testing or sequencing.

Image credit: Sphere Fluidics

Users must know whether the antibody is an IgG or an IgM, before making detection probes that will bind to the target of interest. The assay format is based on a simple FRET reaction, and two detection probes must be encapsulated into the picodroplet along with the cells. One that binds to the Fc region of the antibody and another that targets the antigen on that antibody. Both probes are conjugated to a fluorophore, making a pair of detection probes that can induce a FRET reaction.

When the detection probes are in close proximity, i.e. if they have bound to the Fc and Fab regions of the secreted antibody, they will induce a FRET-mediated shift on fluorescence where the excitation of one probe will transfer energy to the other which will emit a fluorescent signal. Cyto-Mine detects for an energy transfer within the picodroplet, and as the detection probes are customized to target only the antigen of interest, there will not be a fluorescent energy transfer if the antigen of interest isnt present.

Cyto-Mine supports flexible assay design, so the assay format can be tailored to make it specific to the target.

Developed with biopharma in mind, the initial design of Cyto-Mine relied on input from key pharma companies, to solve their most significant challenges and automation was vital to do this.

The current process is incredibly time-consuming and tedious. New techniques need to have a high-throughput, diversity and flexibility of the assay. Rather than automating pipetting, weve made an entirely novel system to approach antibody discovery.

The Cyto-Mine is also applicable to cell line development, where there is a similar need to automate inefficient processes, and Cyto-Mine has single cell imaging and dispensing capacity making it a great fit.

Theres an incredibly high demand for antibody-based biotherapeutics, and its easy to see how successful they are with over 500 antibody-based therapeutics beginning to come through clinical trials. This demand is exemplified with one of the Antibody Societys 20 antibodies to watch in 2020, an antibody against the Ebola virus. The company producing this antibody could stop trials before completion because it was so successful compared to any other treatments.

Over the next decade, the antibody discovery process needs to become quicker, and as new technology is incorporated, should become more rapid. This optimization will shorten the time to market and get new therapeutics in the hands of patients faster.

Dr Zoe Nilsson is the Global Product Marketing Manager for Sphere Fluidics. Zoe has a BSc, MPhil and PhD in Neuroscience and Cell Biology from the University of St Andrews, UK. Zoe works closely with the R&D team to develop new features of Cyto-Mine and novel assay reagent kits to help biopharma customers identify and isolate rare cells of interest.

Zoe is an experienced Product Manager with a demonstrated history of working in the biotechnology industry. Before joining Sphere Fluidics, Zoe led the development of novel cell types from induced pluripotent stem cells (iPSCs) for use in basic research, drug discovery and safety toxicity testing.

Originally posted here:
Accelerating Antibody Discovery with Next-Generation Single-Cell Analysis - News-Medical.net

Cell Biology

Society for Immunotherapy of Cancer to Host Fundamental Two-Day Workshop Focused on Cytokines in Cancer Immunotherapy – PR Web

Because cytokines control many aspects of immune cell biology, we see a resurgent interest in developing these agents either alone or in combination with immune checkpoint modulators for anti-cancer therapy, said SITC President Mario Sznol, MD.

MILWAUKEE (PRWEB) April 22, 2020

The Society for Immunotherapy of Cancer (SITC) will host a new workshop Oct. 1213, 2020, in New York, which will focus on providing a deeper understanding of cytokines in immune cell proliferation, differentiation, and function, as they pertain to tumor immunobiology and cancer immunotherapy approaches.

The SITC Cytokines in Cancer Immunotherapy Workshop is intended for basic, translational and clinical researchers with a vested interest in the topic of cytokine immunology and the impact of cytokines in cancer immunotherapy. The program is organized by prominent members of the immuno-oncology community, including Susan M. Kaech, PhD, from Salk Institute, Anne OGarra, PhD, from The Francis Crick Institute and Aaron Ring, MD, PhD, from Yale University, the workshop will feature oral presentations by leading experts in the field, including keynotes by Warren J. Leonard, MD, from National Heart, Lung, Blood Institute and Harriett Kluger, MD, from Yale University.

Because cytokines control many aspects of immune cell biology, we see a resurgent interest in developing these agents either alone or in combination with immune checkpoint modulators for anti-cancer therapy, said SITC President Mario Sznol, MD. However, there is a great deal we dont yet know about optimal application of the many different cytokines in the clinic, for example how cytokines interact with each other or with agents such as the PD-1/PD-L1 antagonists. We plan to cover current knowledge in this conference and identify potential areas of research that will lead to rational clinical development. The conference will also provide opportunities for young investigators to present their research and to interact with leading senior investigators in the field.

The workshop will aim to foster renewed exchange and research on the promising topic of cytokines and their interactions in cancer development and therapy, lead to further research and provide a solid scientific foundation for future clinical interventions to modulate anti-tumor immunity with combinations of cytokines and other immunotherapies.

The program will also provide an intimate opportunity for attendees to discuss their work with experts in the field, develop collaborations and learn about novel studies of cytokines. Abstract submissions are being accepted through Sept. 1, 2020, from young investigators working with cytokines in their research, including several oral abstract presentation opportunities. These presentations will be judged on scientific merit, and the top presenter from each category will receive a research funding award. Abstract submitters not selected for oral presentation will have the opportunity to present their research as a poster.

The SITC Cytokines in Cancer Immunotherapy Workshop will take place on Oct. 1213, 2020, at the Millennium Times Square New York hotel. Registration rates, criteria for abstract submissions and program schedule are available on SITC Cancer Immunotherapy CONNECT.

About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word cure a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at http://www.sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Share article on social media or email:

Here is the original post:
Society for Immunotherapy of Cancer to Host Fundamental Two-Day Workshop Focused on Cytokines in Cancer Immunotherapy - PR Web

Cell Biology

Researchers uncover how cancer cells don their invisibility cloaks – News-Medical.Net

Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results. But exactly how cancer cells turn on this protein was not completely understood. New research by UT Southwestern Medical Center scientists, published online today in Nature Cancer, lays out key pieces of this mechanism. The findings could offer new targets that may further improve how well current cancer immunotherapies work.

Nearly a decade ago, the Food and Drug Administration approved the first drug in a new class of pharmaceuticals called checkpoint inhibitors. These drugs reverse a cloaking mechanism that many types of cancer cells use to avoid being discovered by the immune system, allowing cancer-fighting immune cells called T cells to attack tumors. Blocking the interaction between one of these cloaking proteins, PD-L1, and its receptor on T cell surfaces forms the basis of several pharmaceuticals currently on the market, including nivolumab, pembrolizumab, and atezolizumab.

Although these drugs have made headway in several types of cancer, notably non-small cell lung cancer (NSCLC) the leading cause of cancer-associated deaths worldwide how cancer cells overexpress PD-L1 to shield themselves from immune system attack has been a mystery.

To help answer that question, Kathryn A. O'Donnell, Ph.D., an associate professor of molecular biology at UT Southwestern, and her colleagues started by looking broadly at which genes might serve as regulators for manufacturing PD-L1 in NSCLC. Using CRISPR, which acts as molecular scissors to remove specific genes, the researchers individually removed 19,000 genes in a human NSCLC cell line. Then, they used a fluorescent PD-L1 antibody to see which cells had more or less PD-L1. This allowed them to identify genes that normally encourage PD-L1 production, or positive regulators, and those that stymie PD-L1 production, or negative regulators.

Surprisingly, they found that a potent inhibitor for the manufacture of PD-L1 is a gene called UROD, which plays a key role in producing heme. This iron-containing chemical is pivotal for carrying oxygen in red blood cells, but is also broadly necessary in other cells for maintaining normal balance, or homeostasis. To confirm these findings, the researchers used other methods to remove heme in NSCLC cells, which also triggered the lung cancer cells to make more PD-L1 protein. When tumors in which UROD was depleted were implanted into healthy mice, they grew significantly faster than those in mice lacking working immune systems. These findings suggest that by activating PD-L1 production, this gene accelerates cancer by suppressing anti-tumor immunity, O'Donnell says.

Further experiments showed that hampering heme production turned on a pathway called the integrated stress response (ISR) that cells broadly use to deal with diverse stress conditions such as low oxygen, toxins, or nutrient starvation. Under these conditions, NSCLC cells used a specialized mechanism, relying on a protein known as eIF5B, to increase PD-L1 production. Just stimulating cells with this single protein could turn up PD-L1 production, the researchers found, even without tampering with heme synthesis.

By examining a database of genes that are over- or underproduced in various cancers, O'Donnell and her team found that the gene encoding eIF5B is frequently overproduced in lung cancers, and that this overproduction in lung cancer patients was a marker for poor prognosis. "Developing new drugs that specifically target this protein, or other proteins involved in making PD-L1, could help improve the success of immunotherapy drugs currently in use," says O'Donnell, also a member of UT Southwestern's Harold C. Simmons Comprehensive Cancer Center.

Investigating the relationship between stress responses and immune evasion in cancer will be an important priority for future work."

Shruthy Suresh, Ph.D., former graduate student researcher and first author of this study

View post:
Researchers uncover how cancer cells don their invisibility cloaks - News-Medical.Net

Cell Biology

A novel method to precisely deliver therapeutics inside the body – Biophotonics.World

A team of Penn State researchers are interfacing chemical biology and nanotechnology to develop ultrasound-controlled nanomaterials that can provide on-demand, high precision delivery of proteins into human cells

Image source: Jennifer McCann/Penn State

A new way to deliver therapeutic proteins inside the body uses an acoustically sensitive carrier to encapsulate the proteins and ultrasound to image and guide the package to the exact location required, according to Penn State researchers. Ultrasound then breaks the capsule, allowing the protein to enter the cell.

"When you expose the particle to ultrasound it opens a hole in the cell membrane that lasts for a couple of microseconds," said Scott Medina, assistant professor of biomedical engineering, Penn State. "We can use this temporary opening to deliver antibodies, which are attractive therapeutic molecules in precision medicine that cannot otherwise get inside cells."

These antibodies are emerging therapeutics for cancers, infectious diseases and rheumatoid arthritis, he said.

But getting the protein inside the nanoparticle carrier was not easy, which is why other researchers have had to resort to complicated and often poorly performing methods, such as attaching the cargo to the exterior of nanoparticles, resulting in inefficient protein release and off-target delivery.

The challenge with the new method was that the protein did not want to interact with the interior of the particle, which is made of a fluorous liquid, similar to liquid Teflon. Medina's doctoral student, Janna Sloand, came up with a creative work around -- a fluorous mask. These chemical masks have a counterbalance of polarity and fluorine content that allows the protein to interact with the fluorous liquid medium while maintaining the protein's folded state and bioactivity.

"We had a lot of challenges developing this new method," said Sloand, first author on the paper published recently inACS Nano. "The most difficult was figuring out what kind of chemicals could mask the protein. That was definitely my eureka moment when I saw that it worked."

In future work, the team will explore the use of their ultrasound-programmable material as a platform for image-guided delivery of therapeutic proteins and gene editing tools.

In related therapeutic applications, they are leveraging this technology to deliver antibodies that can alter abnormal signaling pathways in tumor cells to effectively 'turn-off' their malignant traits. In other work they are delivering gene editing tools, like CRISPR constructs, to enable ultrasound-controlled genome engineering of cells in complex 3D tissue microenvironments.

Importantly, these delivery applications can all be performed using ultrasound techniques already employed in hospitals, which they hope will enable the rapid translation of this technology for precision healthcare.

Source: Penn State

Related journal article:http://dx.doi.org/10.1021/acsnano.9b08745

Read more:
A novel method to precisely deliver therapeutics inside the body - Biophotonics.World

Biochemistry

Biochemistry Analyzers Market Products Report 2020-2026 by Industry Trends and Competition Analysis, Forecast to 2026 – Cole of Duty

Biochemistry Analyzers:

This report studies the Biochemistry Analyzers Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Biochemistry Analyzers Market analysis segmented by companies, region, type and applications in the report.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-and-southeast-asia-biochemistry-analyzers-industry-2018-market-research-report

Biochemistry Analyzers Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Biochemistry Analyzers Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers

Research objectives:

Inquire More about This Report @ https://www.reportsandmarkets.com/enquiry/global-and-southeast-asia-biochemistry-analyzers-industry-2018-market-research-report

The Biochemistry Analyzers Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents: Biochemistry Analyzers Market

Key questions answered in this report

Get Complete Report @ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=2651725

About Us:

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serves our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

View original post here:
Biochemistry Analyzers Market Products Report 2020-2026 by Industry Trends and Competition Analysis, Forecast to 2026 - Cole of Duty

Biochemistry

Global Biochemistry Analysers Market leading key players with impact of covid -19 | HORIBA, Siemens Healthcare, Abbott and Thermo Fisher Scientific -…

The research report explores major market consultation ofGlobalBiochemistry AnalysersMarketafter performing accomplished, intellectual and comprehensive analysis. The report helps key vendors, Biochemistry Analysers manufacturers and end-users of the Biochemistry Analysers market to gain better insights, assets and perspectives. Major topographical zones covered in the Biochemistry Analysers report are the Middle East and Africa, North America, Latin America, Europe, and Asia-Pacific.

Thus topping up conflicting facets of Biochemistry Analysers industry including industrial outlines, schedules, and apparent approaches. It also clears crucial criterions such as company contact information including email address, website addresses, and phone numbers, Biochemistry Analysers industry group, classification, order to supply ratio, sales allowance, cost/price of the product, and key vendors.

Recent vendors that are new to Biochemistry Analysers business find it troublesome to compete with existing market opponent located worldwide. The Biochemistry Analysers market study will be useful for Medical Devices industry executives, product managers, sales, analysts, and consultants. A broad description of plans and policies, product distribution, economic and behavioral policies is also established. Professionals and experts conduct primary and secondary research to gather necessary statistics of the industry by considering SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis. It gives a close idea about raw materials used, innovative technologies, scope and changing arrangements of the marketing channels.

Global Biochemistry Analysers market research report is primarily discriminated as competitors, major geographical regions, product types and applications.

Major dominant players of global Biochemistry Analysers market are

Abbott, Xylem Analytics, Agappe Diagnostics, Siemens Healthcare, HORIBA, RMS, Labindia Instruments, MicroLab Instruments and Thermo Fisher Scientific

Based on Product TypesBiochemistry Analysers marketisolated into

Based on Applications Biochemistry Analysers marketisolated into

On the basis of the geographical study, the Biochemistry Analysers market control over North America, Asia-Pacific, the Middle East and Africa, Latin America, Europe. Considering the global scenario of the Biochemistry Analysers market, North America region is holding to be the biggest market for Biochemistry Analysers. Moreover, the European market is also growing and the second largest market for Biochemistry Analysers. Rest of the World is likely to have a limited but steady expansion in the Biochemistry Analysers business.

Fill the Inquiry Form to Try Sample Copy of Reporthttps://market.biz/report/global-biochemistry-analysers-market-qy/426862/#inquiry

Crystal insights of Biochemistry Analysers market along with market opportunities, threats, and growth is covered in this research report. It inspect present divisions to predict evolving ones and gives detailed segmentation of the industry on the basis of product types, Biochemistry Analysers applications, and major geographical regions. In-depth study of the market share and contribution is also mentioned in the report.

It highlights Biochemistry Analysers leading marketing players along with their different strategies and approaches used. This report study gives information about local, regional and international markets and developing segments. Market dynamics that keeps on changing over time and in-depth scrutiny of the market sources are also cited.

It conducts a deeper study of past and current Biochemistry Analysers market tendencies to predict future market growth in terms of volume and value. It also computes core parameters such as industrial advancements and growth and delivers fundamental market figures in the form of tables, pie charts, graphs and flows charts.

Major applications of Biochemistry Analysers imarketare also determined based on performance and accomplishments. Shrine to industries unsettled to improve their ledge is also discussed.

Usually asked questionson market research report:

1.What are current global Biochemistry Analysers market tendencies, obstructions, and challenges faced by the key competitors of Biochemistry Analysers market?

2.What are major outcomes and consequences of the five strengths study of Biochemistry Analysers industry?

3.What willbe the Biochemistry Analysers market capacity and growth estimation forecast up to 2026?

4.Who are the major players in the global Biochemistry Analysers market and what ways they follow to increase overall revenue?

5.What are the durabilities and defects of the Biochemistry Analysers industry?

At the end, the Global Biochemistry Analysers Market report delivers high-level information both in terms of quality and quantity. It also gives a summary of the Biochemistry Analysers vendor, dealer, contributors to the market along with research findings, data source, and appendix.

Get in touch with Us:

420 Lexington Avenue Suite 300

New York City, NY 10170, United States

USA/Canada Tel No:+1-857-2390696

Email:[emailprotected]

Website:https://market.biz/

Go here to read the rest:
Global Biochemistry Analysers Market leading key players with impact of covid -19 | HORIBA, Siemens Healthcare, Abbott and Thermo Fisher Scientific -...

Biochemistry

Biochemistry Analyzers Market Projected to Witness a Double-Digit CAGR During 2020 to 2026 – Surfacing Magazine

Biochemistry AnalyzersMarket Report 2020-2026includes a comprehensive analysis of the present Market. The report starts with the basic Biochemistry Analyzers industry overview and then goes into each and every detail.

Biochemistry Analyzers Market Report contains in-depth information on major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Biochemistry Analyzers also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Biochemistry Analyzers Market competition by top manufacturers/players, with Biochemistry Analyzers sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including Abbott, Danaher Corporation, F.Hoffman-La Roche Ltd., Siemens AG, Thermo Fisher Scientific, Inc., Randox Laboratories Ltd., Meril, Hologic Inc., Beckman Coulter Inc., and Horiba Medical.

Ask for Sample Copy of the Report: @ https://www.coherentmarketinsights.com/insight/request-sample/1873

Important Features that are under offering & key highlights of the report:

1) What all regional segmentation covered? Can the specific country of interest be added?Currently, the research report gives special attention and focus on the following regions:North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

2) What all companies are currently profiled in the report?The report Contain the Major Key Players currently profiled in this market.** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Can we add or profiled new company as per our need?Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by the research team depending upon the difficulty of the survey.** Data availability will be confirmed by research in case of a privately held company. Up to 3 players can be added at no added cost.

4) Can the inclusion of additional Segmentation / Market breakdown is possible?Yes, the inclusion of additional segmentation / Market breakdown is possible to subject to data availability and difficulty of the survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.** Depending upon the requirement the deliverable time and quote will vary.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1873

Biochemistry Analyzers Market Dynamics in the world mainly, the worldwide 2018-2026 Biochemistry Analyzers Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Region Segmentation:

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Key questions answered in the report:

1. What will the market growth rate of Biochemistry Analyzers market in 20262. What are the key factors driving the global Biochemistry Analyzers market3. Who are the key manufacturers in Biochemistry Analyzers market space?4. What are the market opportunities, market risk and market overview of the Biochemistry Analyzers market?5. What are sales, revenue, and price analysis by types and applications of Biochemistry Analyzers market?6. What are sales, revenue, and price analysis by regions of Biochemistry Analyzers industry?

Further in the report, the Biochemistry Analyzers market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Biochemistry Analyzers industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Ask Query for more details @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1873

In this study, the years considered to estimate the market size of 2018-2026 Biochemistry Analyzers Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

View post:
Biochemistry Analyzers Market Projected to Witness a Double-Digit CAGR During 2020 to 2026 - Surfacing Magazine